April 22, 2024

bioRN M2M Member to Member featuring IKTZ

bioRN M2M Member to Member featuring IKTZ
Go back

The IKTZ Heidelberg is a non-profit transfusion medical service provider and blood donation center in the Heidelberg region. A joint venture of the Red Cross Blood Donor Service Baden-Württemberg Hessen and University Hospital Heidelberg, IKTZ supplies blood products, diagnostics, and therapeutic procedures to local clinics. Its Stem Cell Laboratory, operational since July 1, 2011, produces and stores stem cell preparations for the Heidelberg University Hospital’s transplantation program, aiding patients with bone marrow diseases.

register now

Our latest News

discover more
Medizin im digitalen Zeitalter: Forum Gesundheitsstandort präsentiert Technologie-Projekte bei der DMEA 2025

Medizin im digitalen Zeitalter: Forum Gesundheitsstandort präsentiert Technologie-Projekte bei der DMEA 2025

(Stuttgart, 26.03.2025)  Daten retten Leben. Denn mit neuen Technologien und mit der Unterstützung von Künstlicher Intelligenz lassen sich riesige Mengen medizinischer Daten verlässlicher als je zuvor auswerten. So können Krankheiten frühzeitiger erkannt und behandelt werden. Dazu aber gilt es, die Daten optimal miteinander zu vernetzen, damit Ärztinnen, Ärzte, Kliniken und Pflegende ihre Patientinnen und Patienten bestmöglich […]

read more
How chromosomes shape up for cell division

How chromosomes shape up for cell division

EMBL scientists have shown how overlapping loops of DNA stack upon each other in dividing cells to give rise to rod-shaped chromosomes Summary Among the many marvels of life is the cell’s ability to divide and thus enable organisms to grow and renew themselves. For this, the cell must duplicate its DNA – its genome […]

read more
Resistance mechanism in chronic lymphocytic leukemia identified

Resistance mechanism in chronic lymphocytic leukemia identified

Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp